The #Cantabio Pharmaceuticals team looks forward to participating in the Singapore Healthcare Engineering Forum 2024 on October 3-4, 2024 in Singapore. Dr. Tóth, CEO & CSO, will be presenting on Cantabio's precision therapeutic and diagnostic R&D programs for Parkinson's Disease.
Cantabio Pharmaceuticals, Inc.
制药业
Sunnyvale，CA 800 位关注者
Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.
关于我们
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug discovery technology and expertise into an innovative drug discovery approach, which is currently identifying and developing small molecule pharmacological chaperones for clinical trials. In addition, the company is developing therapeutic proteins that can pass through the blood-brain barrier to supplement existing levels of proteins which display loss of function during disease conditions.
- 网站
-
https://www.cantabio.com
Cantabio Pharmaceuticals, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Sunnyvale，CA
- 类型
- 上市公司
地点
Cantabio Pharmaceuticals, Inc.员工
动态
-
Dr. Tóth, CEO of #Cantabio Pharmaceuticals, presented on the company’s novel precision therapeutic projects targeting #Parkinsons disease at the Hong Kong International Biotechnology Convention on September 13th, 2024.
-
-
Dr. Tóth, CEO of #Cantabio Pharmaceuticals, will present on the company’s novel therapeutic projects targeting #Alzheimers and #Parkinsons diseases at EFMC-ISMC conference in Rome, Italy on September 3, 2024.
-
-
Cantabio Pharmaceuticals, Inc.转发了
?? Many thanks to Gergely Toth, Cantabio Pharmaceuticals, Inc., for presenting us the research he is performing to develop innovative therapies for Parkinson's disease! ??? Undoubtedly, DJ-1 based precision therapies are a promising way of fighting neurodegenerative diseases. After the talk, we headed to Darwin College, University of Cambridge for a #formal dinner where we kept discussing about #Longevity, #Bioscience and #Entrepreneurship ?? ?? Find our recording of the talk at https://lnkd.in/dRJjKqYr
-
-
-
-
-
+1
-
-
Dr. Tóth, CEO of #Cantabio Pharmaceuticals, presented the company’s novel therapeutic and diagnostic programs for #Alzheimers and #Parkinsons diseases at The First Chinese Biopharmaceutical Association CBA-China Annual Conference in 2024 on June 29, 2024.
-
-
Balázs Fórizs, Head of Biochemistry & Biophysics at?#Cantabio?Pharmaceuticals, is presenting on the company’s proprietary therapeutic program targeting the reduction of Tau protein aggregation using novel pharmacological chaperones for?#Alzheimers?and?#Parkinsons?at Discovery Europe 2024 (#ogdiscovery) ?in Basel on May 22, 2024.
-
-
Cantabio Pharmaceuticals, Inc.转发了
Cantabio's CEO will be presenting about the company's novel research efforts on therapeutic targeting of the DJ-1 protein for Parkinson's disease at a lecture organized by Cambridge Society of Ageing and Longevity Research.
?? Join us for an enlightening presentation on "The Pathway to DJ-1 Based Precision Therapies for Parkinson’s by Maintaining Cellular Redox Homeostasis." by Gergely Toth together with Darwin Entrepreneurs Club. ???? Abstract ???? This talk will explore the critical role of DJ-1 protein in cellular survival, its connection to redox homeostasis, and the implications for aging-related diseases. Discover how oxidative stress leads to DJ-1 dysfunction, contributing to both familial and sporadic Parkinson’s disease. The session will also cover innovative therapeutic strategies targeting DJ-1, including pharmacological chaperones and enzyme replacement therapies, aimed at combating Parkinson’s. Additionally, learn about the potential of using various oxidized states of DJ-1 as biomarkers for Parkinson’s disease, assessed through novel ELISA techniques. This presentation will be extremely insightful for those interested in the latest advancements in neurodegenerative disease research and therapy. ????About Gergely???? Gergely Tóth (PhD, MBA) is the CEO, CSO and founder of Cantabio Pharmaceuticals, Inc. (USA), a preclinical stage biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. In addition, Dr. Tóth is an Honorary Associate Professor at the School of Pharmacy at University College London lecturing to graduate students on topics as the business of biotech and bioentrepreneurship. Look Forward to Seeing you There! ??
-
-
Cantabio Pharmaceuticals, Inc.转发了
Cantabio's CEO will be presenting about the company's novel research efforts on therapeutic targeting of the DJ-1 protein for Parkinson's disease at a lecture organized by Cambridge Society of Ageing and Longevity Research.
?? Join us for an enlightening presentation on "The Pathway to DJ-1 Based Precision Therapies for Parkinson’s by Maintaining Cellular Redox Homeostasis." by Gergely Toth together with Darwin Entrepreneurs Club. ???? Abstract ???? This talk will explore the critical role of DJ-1 protein in cellular survival, its connection to redox homeostasis, and the implications for aging-related diseases. Discover how oxidative stress leads to DJ-1 dysfunction, contributing to both familial and sporadic Parkinson’s disease. The session will also cover innovative therapeutic strategies targeting DJ-1, including pharmacological chaperones and enzyme replacement therapies, aimed at combating Parkinson’s. Additionally, learn about the potential of using various oxidized states of DJ-1 as biomarkers for Parkinson’s disease, assessed through novel ELISA techniques. This presentation will be extremely insightful for those interested in the latest advancements in neurodegenerative disease research and therapy. ????About Gergely???? Gergely Tóth (PhD, MBA) is the CEO, CSO and founder of Cantabio Pharmaceuticals, Inc. (USA), a preclinical stage biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. In addition, Dr. Tóth is an Honorary Associate Professor at the School of Pharmacy at University College London lecturing to graduate students on topics as the business of biotech and bioentrepreneurship. Look Forward to Seeing you There! ??
-
-
Cantabio's CEO will be presenting about the company's novel research efforts on therapeutic targeting of the DJ-1 protein for Parkinson's disease at a lecture organized by Cambridge Society of Ageing and Longevity Research.
?? Join us for an enlightening presentation on "The Pathway to DJ-1 Based Precision Therapies for Parkinson’s by Maintaining Cellular Redox Homeostasis." by Gergely Toth together with Darwin Entrepreneurs Club. ???? Abstract ???? This talk will explore the critical role of DJ-1 protein in cellular survival, its connection to redox homeostasis, and the implications for aging-related diseases. Discover how oxidative stress leads to DJ-1 dysfunction, contributing to both familial and sporadic Parkinson’s disease. The session will also cover innovative therapeutic strategies targeting DJ-1, including pharmacological chaperones and enzyme replacement therapies, aimed at combating Parkinson’s. Additionally, learn about the potential of using various oxidized states of DJ-1 as biomarkers for Parkinson’s disease, assessed through novel ELISA techniques. This presentation will be extremely insightful for those interested in the latest advancements in neurodegenerative disease research and therapy. ????About Gergely???? Gergely Tóth (PhD, MBA) is the CEO, CSO and founder of Cantabio Pharmaceuticals, Inc. (USA), a preclinical stage biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. In addition, Dr. Tóth is an Honorary Associate Professor at the School of Pharmacy at University College London lecturing to graduate students on topics as the business of biotech and bioentrepreneurship. Look Forward to Seeing you There! ??
-
-
Cantabio Pharmaceuticals, Inc.转发了
Cantabio Pharmaceuticals announces the award of a major grant from The Michael J. Fox Foundation for Parkinson’s Research for the Development of a Novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease https://lnkd.in/dazEAHGM